Based on the current earnings figures, this year's price targets for ImmunoPrecise Antibodies were recently set by distinguished experts, with an average mark of $7.00. If it reached this goal, it would represent a potential upside of approximately 460% from the previous closing price in May, 2024. The high end is $9.00, and the low is $5.00. If you are not interested in IPA stock, you may be interested in its competitors.

$7.00

460.00% Upside

Buy

ImmunoPrecise Antibodies Fair Value Forecast for 2023 - 2025 - 2030

ImmunoPrecise Antibodies's Price has seen growth In the last year, going from $0.00 to $0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach $0.00 – an increase of 100.00%. For the next five years, the forecast is forFair Value to grow by 100.00%.

2026 Fair Value Forecast

$0.00

2027 Fair Value Forecast

$0.00

2028 Fair Value Forecast

$0.00

2029 Fair Value Forecast

$0.00

2030 Fair Value Forecast

$0.00

ImmunoPrecise Antibodies Revenue Forecast for 2023 - 2025 - 2030

ImmunoPrecise Antibodies's Revenue has seen growth In the last three years, going from $14.06M to $20.67M – a gain of 47.01% In the following year, the 0 analysts surveyed believe that ImmunoPrecise Antibodies's Revenue will decrease by 11.78%, reaching $18.24M. According to professionals, by 2030, ImmunoPrecise Antibodies's Revenue will have decreased by 9.55%, falling down to $18.70M.

2024 Rev Forecast

$0.02B

2025 Rev Forecast

$0.02B

2026 Rev Forecast

$0.02B

2027 Rev Forecast

$0.02B

2028 Rev Forecast

$0.02B

2029 Rev Forecast

$0.02B

2030 Rev Forecast

$0.02B

ImmunoPrecise Antibodies Dividend per Share Forecast for 2023 - 2025 - 2030

ImmunoPrecise Antibodies Free Cash Flow Forecast for 2023 - 2025 - 2030

ImmunoPrecise Antibodies EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, ImmunoPrecise Antibodies's EBITDA has increased by 831.38%, going from $-2.39M to $-22.26M. For the next year, 0 analysts project ImmunoPrecise Antibodies's EBITDA to drop by 50.35%, reaching $-11.05M. By 2030, professionals believe that ImmunoPrecise Antibodies's EBITDA will decrease by 37.96%, reaching $-13.81M – a concerning trend for the company.

2024 EBITDA Forecast

$-11051348.00

2025 EBITDA Forecast

$-10992407.48

2026 EBITDA Forecast

$-13459103.72

2027 EBITDA Forecast

$-17211053.19

2028 EBITDA Forecast

$-14939767.87

2029 EBITDA Forecast

$-13698273.16

2030 EBITDA Forecast

$-13810599.00

ImmunoPrecise Antibodies EBIT Forecast for 2023 - 2025 - 2030

In the last three years, ImmunoPrecise Antibodies's EBIT has grown, increasing from $-4.10M to $-26.09M – an increase of 536.34%. According to 0 prominent analysts, ImmunoPrecise Antibodies's EBIT will fall by 45.24% in the next year, reaching $-14.29M. By 2030, professionals believe that ImmunoPrecise Antibodies's EBIT will decrease by 37.26%, reaching $-16.37M – a concerning trend for the company.

2024 EBIT Forecast

$-14286014.33

2025 EBIT Forecast

$-13583618.63

2026 EBIT Forecast

$-15769675.65

2027 EBIT Forecast

$-19656375.05

2028 EBIT Forecast

$-17791640.27

2029 EBIT Forecast

$-16418718.69

2030 EBIT Forecast

$-16367820.66

ImmunoPrecise Antibodies EPS Price Prediction Forecast for 2023 - 2025 - 2030

ImmunoPrecise Antibodies's EPS has seen growth In the last year, going from $-0.81 to $0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach $0.00 – an increase of 100.00%. For the next five years, the forecast is forEPS to grow by 100.00%.

2026 EPS Forecast

$0.00

2027 EPS Forecast

$0.00

2028 EPS Forecast

$0.00

2029 EPS Forecast

$0.00

2030 EPS Forecast

$0.00